Ovid Therapeutics Inc.
NASDAQ:OVIDBiotechnology
-$0.11 today
- Market cap
- $426.53M
- Beta
- 0.18
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.33
Volume 2.16M
Average 3.07M
OVID EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Ovid Therapeutics Inc.NASDAQ: OVID
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$16.95M, compared with -$10.09M a year earlier. Trailing-twelve-month EBITDA was -$24M.
Context
- EBITDA amounted to 236.0% of revenue in FY2025, down 9971.1 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of -$29.21M (-70.7%) for the fiscal year ending Dec 2026, a slowdown from the +70.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$16.95M-275.1% QoQ
- Last fiscal yearDec 2025
- -$17.11M+70.4% YoY
- LTMMar 2026
- -$24M+7.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -68.0% | -408.9% | -340.9 pp |
| 1 year | +70.4% | -70.7% | -141.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (17.11M) USD
- Year-over-year change
- +70.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (17.11M) | +70.4% |
| FY2024 | 2024-12-31 | (57.77M) | -1.3% |
| FY2023 | 2023-12-31 | (57.01M) | -5.3% |
| FY2022 | 2022-12-31 | (54.17M) | -143.5% |
| FY2021 | 2021-12-31 | 124.45M | — |
EBITDA vs competitors
How OVID compares with its peers on the latest reported figures
- OVID's LTM Mar 2026 EBITDA of -$24M is the 2nd highest of the 11 companies compared; the peer median is -$130.65M.
- Its year-over-year change of +7.8% is the 5th highest of 11, against a peer median of -17.4%.
- EBITDA amounts to 337.0% of revenue for OVID, versus a peer median of 308.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $73.43M | +298.8% | — | 505.0% | |
| LTM Mar 2026 | -$24M | +7.8% | — | 337.0% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$85.19M | +20.5% | — | — |
| LTM Mar 2026 | -$95.45M | -22.9% | — | — | |
| LTM Mar 2026 | -$95.72M | +32.5% | — | 120.0% | |
| LTM Mar 2026 | -$112.54M | -37.5% | — | 308.4% | |
| LTM Jun 2026 | -$148.77M | -62.6% | — | 2712.3% | |
| LTM Mar 2026 | -$164.11M | -405.9% | — | 511.5% | |
| LTM Mar 2026 | -$174.59M | -68.4% | — | 243.2% | |
| LTM Mar 2026 | -$194.47M | +21.0% | — | — | |
| LTM Mar 2026 | -$503.35M | -11.9% | — | 75.2% | |
| Peer median (excluding OVID) | -$130.65M | -17.4% | — | 308.4% | |
Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 208.38M | 1.5M | 392K | 566K | 7.25M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 300K |
| Gross Profit | 208.38M | 1.5M | 392K | 566K | 6.95M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.9% |
| Research & Development | 46.94M | 24.62M | 28.59M | 36.77M | 25.58M |
| Selling, General & Admin | 37.23M | 32.43M | 29.59M | 25.68M | 24.11M |
| Operating Expenses | 84.17M | 57.05M | 59.67M | 62.45M | 49.39M |
| Depreciation & Amortization | 237.08K | 1.38M | 568K | 613K | 300K |
| EBITDA | 124.45M | (54.17M) | (57.01M) | (57.77M) | (17.11M) |
| EBITDA Margin | 59.7% | -3604.5% | -14544.1% | -10207.1% | -236.0% |
| Operating Income | 124.21M | (55.55M) | (59.28M) | (61.89M) | (42.44M) |
| Operating Margin | 59.6% | -3696.4% | -15122.7% | -10933.7% | -585.2% |
| Interest Income | 0 | 0 | 4.9M | 3.9M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (45.69K) | 1.38M | 6.94M | 35.45M | 25.03M |
| Income Before Tax | 124.16M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Pre-Tax Margin | 59.6% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
| Income Tax Expense | 1.33M | 0 | 0 | 0 | 0 |
| Net Income | 122.83M | (54.17M) | (52.34M) | (26.43M) | (17.41M) |
| Net Margin | 58.9% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
| EPS (Basic) | 1.78 | (0.77) | (0.74) | (0.37) | (0.24) |
| EPS (Diluted) | 1.76 | (0.77) | (0.74) | (0.37) | (0.24) |
| Weighted Avg Shares | 67.48M | 70.43M | 70.58M | 70.91M | 73.74M |
| Weighted Avg Shares (Diluted) | 68.07M | 70.43M | 70.58M | 70.91M | 73.74M |
Ovid Therapeutics Inc.
NASDAQ:OVID
Intrinsic Alpha fair value
Locked
Current Price
$2.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.